Oncology Research Editorial Office

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.077269 - 30 December 2025

Abstract This article has no abstract. More >

Se Ha Jang^1,2,#, Hyung Seok Kim^3,#, Jung Woo Eun^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.072240 - 30 December 2025

Abstract Hepatocellular carcinoma (HCC) remains one of the most prevalent and lethal malignancies worldwide. Long non-coding RNAs (lncRNAs) have emerged as crucial regulators of gene expression and cancer progression, yet the functional diversity of RP11-derived lncRNAs—originally mapped to bacterial artificial chromosome (BAC) clones from the Roswell Park Cancer Institute—has only recently begun to be appreciated. This mini-review aims to systematically synthesize current findings on RP11-derived lncRNAs in HCC, outlining their genomic origins, molecular mechanisms, and biological significance. We highlight their roles in metabolic reprogramming, microRNA network modulation, and tumor progression, as well as their diagnostic and More >

Wen-Shou Tan^1,#, Hsuan Kuo^2,#, Chang-Ge Jiang¹, Mei-Han Lu¹, Yi-He Lu¹, Yung-Li Wang¹, Ching-Shuen Wang¹, Thi Thuy Tien Vo³, I-Ta Lee^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070871 - 30 December 2025

Abstract This narrative review examines recent advances in salivary biomarkers for oral squamous cell carcinoma (OSCC), a major subtype of oral cancer with persistently low five-year survival rates due to delayed diagnosis. Saliva has emerged as a noninvasive diagnostic medium capable of reflecting both local tumor activity and systemic physiological changes. Various salivary biomarkers, including microRNAs, cytokines, proteins, metabolites, and exosomes, have been linked to oncogenic signaling pathways involved in tumor progression, immune modulation, and therapeutic resistance. Advances in quantitative polymerase chain reaction, mass spectrometry, and next-generation sequencing have enabled comprehensive biomarker profiling, while point-of-care detection More >

Giacomo Iovane^1,*, Luca Traman², Michele Maffezzoli^1,3, Giuseppe Fornarini², Domenico Corradi⁴, Debora Guareschi⁴, Matteo Santoni^5,#, Sebastiano Buti^1,#

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070523 - 30 December 2025

Abstract Background: While the treatment of metastatic renal cell carcinoma (mRCC) is evolving due to immune checkpoint inhibitors (ICIs), optimal strategies for later lines of therapy have yet to be defined. The combination of lenvatinib and everolimus represents a viable option, and the present review aimed to summarize its activity, effectiveness, and safety. Methods: A systematic review of the literature was conducted using PubMed, targeting studies published between 2018 and 2025. Eligible studies included English-language prospective and retrospective trials reporting survival outcomes in mRCC patients treated with lenvatinib and everolimus after at least one ICI-containing regimen. Results:… More > Graphic Abstract

Lv Ling^1,#, Minying Lu^2,#, Ling Ye³, Yuanhang Chen², Sheng Lin², Jun Yang², Yu Rong^2,*, Guixiong Wu^4,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.069889 - 30 December 2025

Abstract Background: A significant proportion of patients still cannot benefit from existing targeted therapies and immunotherapies, making the search for new treatment strategies extremely urgent. In this study, we combined integrate public data analysis with experimental validation to identify novel prognostic biomarkers and therapeutic targets for lung adenocarcinoma (LUAD). Methods: We analyzed RNA and protein databases to assess the expression levels of cytochrome C oxidase 5B (COX5B) in LUAD. Several computational algorithms were employed to investigate the relationship between COX5B and immune infiltration in LUAD. To further elucidate the role of COX5B in LUAD, we utilized… More > Graphic Abstract

Yongle Qiu^1,#, Kunshan Li^1,#, Wenjing Wang¹, Wenjuan Zhang², Jilun Liu², Yang Bai³, Fei Xu³, Jie Guo^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.069612 - 30 December 2025

Abstract Background: The regulatory mechanisms governing vasculogenic mimicry (VM) in oral squamous cell carcinoma (OSCC) remain largely undefined. This study aimed to identify critical factors and elucidate the epigenetic mechanisms underlying VM in OSCC. Methods: Bioinformatics analysis was performed utilizing single-cell RNA-seq, bulk RNA-seq, and histone H3 lysine 27 acetylation (H3K27ac) Chromatin Immunoprecipitation (ChIP)-seq data obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. ChIP-qPCR was used to validate the binding of ETS transcription factor ELK4 (ELK4) to the dihydrofolate reductase (DHFR) enhancer. In vitro VM formation and invasion of OSCC cells were… More > Graphic Abstract

Huihui Shi^1,#, Lei Chen^2,#, Juan Huang^3,#, Xuejing Lin², Lei Huang⁴, Min Tang⁴, Kai Lu^5,*, Wenchao Wang^4,*, Maoling Zhu^1,§,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.068737 - 30 December 2025

Abstract Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. This study aimed to identify key genes involved in HCC development and elucidate their molecular mechanisms, with a particular focus on mitochondrial function and apoptosis. Methods: Differential expression analyses were performed across three datasets—The Cancer Genome Atlas (TCGA)-Liver Hepatocellular Carcinoma (LIHC), GSE36076, and GSE95698—to identify overlapping differentially expressed genes (DEGs). A prognostic risk model was then constructed. Cysteine/serine-rich nuclear protein 1 (CSRNP1) expression levels in HCC cell lines were assessed via western blot (WB) and quantitative reverse transcription polymerase chain reaction (qRT-PCR).… More > Graphic Abstract

Song Xu^1,2,3,4,5,*, Mengxin Lu^1,2,3,4,5, Zhonghua Yang^1,2,3,4,5, Hang Zheng^1,2,3,4,5

Canadian Journal of Urology, Vol.32, No.6, pp. 579-588, 2025, DOI:10.32604/cju.2025.063069 - 30 December 2025

Abstract Background: Many studies have evaluated the performance of fluorescence in situ hybridization (FISH) in detecting urothelial carcinoma, while few of them compared it in detecting bladder cancer (BC) vs. upper tract urothelial carcinoma (UTUC). This study aimed to determine and compare the FISH performance in detecting BC and UTUC. Methods: Data of patients with suspected urothelial carcinoma (UC) who accepted FISH from January 2021 to April 2023 were retrieved. The sensitivity and specificity of FISH in detecting BC and UTUC were determined and compared. Results: A total of 145 BC, 62 UTUC, and 170 non-UC patients were… More >

Woo-Gyun Choi, Byung Joo Kim^*

BIOCELL, Vol.49, No.12, pp. 2365-2375, 2025, DOI:10.32604/biocell.2025.072715 - 24 December 2025

Abstract Objectives: Petasites japonicus (PJ) is a traditional medicinal herb widely used in East Asia for treating diverse ailments. However, its anticancer properties and underlying mechanisms have not been elucidated. This study investigated the anticancer potential and molecular mechanisms of the methanol extract of Petasites japonicus (PJE) in human adenocarcinoma gastric stomach (AGS) cells. Methods: AGS cells were treated with various concentrations of PJE, and cell viability was measured using MTT and CCK-8 assays. Apoptotic cell death was evaluated by the cell cycle, caspase-3 and -9 activity assays, and western blotting. To elucidate the underlying signaling mechanisms, we… More >

Boxuan Han^1,2,#, Shaokun Liu^3,#, Ridhima Das³, Shiqian Liu⁴, Yang Zhang^1,2,*

Oncology Research, Vol.33, No.12, pp. 3633-3656, 2025, DOI:10.32604/or.2025.071296 - 27 November 2025

Abstract Organoid technology, characterized by high fidelity in mimicking the in vivo microenvironment, preservation of tumor heterogeneity, and capacity for high-throughput operations, has emerged as a critical tool in head and neck cancer research. To address clinical challenges in head and neck cancer management—including marked tumor heterogeneity, therapeutic resistance, and significant prognostic variability—this review focuses on four key translational applications of organoid technology: In mechanistic studies, organoid models provide a reliable platform for investigating tumorigenesis, progression, and drug resistance mechanisms. In personalized therapy, organoid-based drug sensitivity testing enables data-driven clinical decision-making. For biomarker discovery, organoids facilitate the More >